X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Wockhardt with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs ACTAVIS (US) - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 WOCKHARDT LTD.   ACTAVIS
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
ACTAVIS
Dec-14
WOCKHARDT LTD./
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,12917,533-   
Low Rs62710,695-   
Sales per share (Unadj.) Rs363.13,157.2-  
Earnings per share (Unadj.) Rs-20.4-394.0-  
Cash flow per share (Unadj.) Rs-7.0289.7-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs301.86,847.8-  
Shares outstanding (eoy) m110.55265.90-   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x2.44.5 54.1%   
Avg P/E ratio x-42.9-35.8 119.9%  
P/CF ratio (eoy) x-125.948.7 -258.3%  
Price / Book Value ratio x2.92.1 141.1%  
Dividend payout %-48.90-   
Avg Mkt Cap Rs m97,0633,752,831 2.6%   
No. of employees `0006.821.6 31.3%   
Total wages/salary Rs m9,6650-   
Avg. sales/employee Rs Th5,931.838,865.5 15.3%   
Avg. wages/employee Rs Th1,428.10-   
Avg. net profit/employee Rs Th-334.0-4,850.0 6.9%   
INCOME DATA
Net Sales Rs m40,146839,495 4.8%  
Other income Rs m1,143-2,095 -54.5%   
Total revenues Rs m41,289837,400 4.9%   
Gross profit Rs m128107,845 0.1%  
Depreciation Rs m1,489181,781 0.8%   
Interest Rs m2,25326,479 8.5%   
Profit before tax Rs m-2,472-102,511 2.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,520 0.0%   
Tax Rs m-211-5,270 4.0%   
Profit after tax Rs m-2,260-104,760 2.2%  
Gross profit margin %0.312.8 2.5%  
Effective tax rate %8.55.1 166.1%   
Net profit margin %-5.6-12.5 45.1%  
BALANCE SHEET DATA
Current assets Rs m46,160442,306 10.4%   
Current liabilities Rs m19,258322,571 6.0%   
Net working cap to sales %67.014.3 469.8%  
Current ratio x2.41.4 174.8%  
Inventory Days Days10158 173.6%  
Debtors Days Days9466 141.9%  
Net fixed assets Rs m40,165102,511 39.2%   
Share capital Rs m5530-   
"Free" reserves Rs m32,8140-   
Net worth Rs m33,3671,820,833 1.8%   
Long term debt Rs m31,903954,152 3.3%   
Total assets Rs m89,6873,336,988 2.7%  
Interest coverage x-0.1-2.9 3.4%   
Debt to equity ratio x1.00.5 182.5%  
Sales to assets ratio x0.40.3 177.9%   
Return on assets %0-2.3 0.4%  
Return on equity %-6.8-5.8 117.7%  
Return on capital %-0.3-3.0 11.1%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m6,9880-   
CASH FLOW
From Operations Rs m-2,695144,158 -1.9%  
From Investments Rs m-6,863-345,168 2.0%  
From Financial Activity Rs m12,545193,935 6.5%  
Net Cashflow Rs m3,010-7,076 -42.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare WOCKHARDT LTD. With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare WOCKHARDT LTD. With: VENUS REMEDIES  PLETHICO PHARMA  LUPIN LTD  SUN PHARMA  ALKEM LABORATORIES  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Feb 19, 2018 03:37 PM

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - GSK PHARMA COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS